Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Get Attitude, Drive Cultural Transformation, Fred Hassan Tells Execs At TAP

This article was originally published in The Pink Sheet Daily

Executive Summary

Cultural transformation was the main topic of Warburg Pincus managing director Fred Hassan’s keynote talk at the Therapeutic Area Partnerships meeting on Nov. 19, where the audience also drew on the investor’s extensive track record leading some of pharma’s most successful turnarounds.

You may also be interested in...

Priority Of Merck's Integration Of Schering Is Retaining Top R&D Talent - Kim

Merck's acquisition of Schering-Plough won't close until the fourth quarter, but the drug maker is already wading through a pipeline review to determine which research programs will get a green light as part of the combined company and which ones might get shelved

What Fred Said: Schering-Plough's Hassan On Life In Big Pharma

Fred Hassan's days as chairman of Schering-Plough are numbered, and he hasn't indicated his next step once his company's merger with Merck closes, likely later this year. He remained cagey - giving only a few indirect clues about his preferences in an interview held Sept. 23 as part of Windhover's Pharmaceutical Strategic Alliances conference in New York City

Schering’s Organon Grab Made Merck's Merger Magic Happen

Takeover in 2007 proved no permanent fix for Schering, but it was enough to lure an even bigger deal.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts